Here’s to why Ardelyx Inc. (ARDX) stock surges during current market trading session?

0
472
GILD Stock
GILD Stock

Ardelyx Inc. (NASDAQ: ARDX) stock gained by 1.03% in the current market trading session. Ardelyx is dedicated to discovering, developing, and promoting novel first-in-class medications that will improve the lives of people suffering from kidney and cardiorenal illnesses.

>> 7 Top Picks for the Post-Pandemic Economy << 

ARDX stock’ Current Development

The results of Ardelyx’s 52-week Phase 3 PHREEDOM trial have been published in Kidney360, the journal of the American Society of Nephrology.


China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored


Read More

Mike Raab, president, and chief executive officer of Artily said that the PHREEDOM experiment, a 52-week randomized Phase 3 trial evaluating tenapanor monotherapy, was the third of three Phase 3 trials they performed in the complete investigation of tenapanor for serum phosphorus management in patients on dialysis with chronic kidney disease. The PHREEDOM results show that tenapanor can reduce phosphorus levels significantly while maintaining a level of long-term safety that is comparable to active control.

This research, combined with results from their AMPLIFY trial, demonstrates the critical role that tenapanor, with its new blocking action, can serve in the treatment of hyperphosphatemia in patients on dialysis with serious kidney disease.

Arnold Silva, director of Clinical Research at Boise Kidney and Hypertension Institute, further stated,

As a researcher in this clinical research and an author on this paper, he had the chance to see the influence of tenapanor on serum phosphorus management firsthand and in bulk. He feels that this innovative mechanism therapy will be critical in improving the treatment of hyperphosphatemia in the dialysis patients with CKD. Therapy options have been restricted in this area, and despite treatment response with currently available medications, a significant proportion of patients have phosphorus levels above goal values. Furthermore, whether taken alone or in conjunction with phosphate binders, a one pill twice daily therapy that limits phosphorus absorption has the potential to lessen treatment burden, which will be a substantial advantage to patients.

LEAVE A REPLY

Please enter your comment!
Please enter your name here